Intended Use

The AHI System is intended for use by healthcare professionals managing patients 18 years or older who are receiving continuous physiological monitoring with electrocardiography (ECG) in hospitals to describe a patient's hemodynamic status and indicate signs of stability or instability.

Technology

The system analyzes lead-II ECG waveform data using AI to detect signs of hemodynamic instability and predicts likelihood of future instability episodes using outputs from the analytics. It provides binary and risk-level outputs updated frequently, incorporating heart rate variability and ECG morphology features.

Performance

Clinical validation compared AHI-PI outputs to invasively monitored vital signs in hospitalized patients, demonstrating significant discrimination between risk groups and showing the high-risk indicator to be 51 times more likely to predict hemodynamic instability in the next hour. A median lead time of 48 minutes for prediction was reported, with positive results from software verification, usability studies, and clinical data.

Predicate Devices

No predicate devices specified

Device Timeline

  • 1

    Submission

    7/16/2021

    4 months
  • 2

    FDA Approval

    12/3/2021

Other devices from Fifth Eye Inc.

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.